Major Adverse Cardiovascular Events — a composite endpoint typically combining cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
The standard cardiovascular-safety endpoint for diabetes and obesity drugs. Semaglutide reduced MACE by 26% in SUSTAIN-6 and 20% in SELECT. MACE composites are sometimes expanded (3-point, 4-point, 5-point) to include heart-failure hospitalization or unstable angina.